Physician profile
Brian Levin
NPI 1164479507
$7,891.00
in general payments reported to CMS, 2019-2025
50 companies · $2,285 in 2025
The $2,285 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $165 · 2021: $1,127 · 2022: $1,051 · 2023: $1,009 · 2024: $1,574 · 2025: $2,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,833 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,832.65 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $821.95 | 2023-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $793.42 | 2021-2025 | Barrigel, Urolift |
| Olympus America INC. | $661.96 | 2023-2025 | Itind System, Uretero-Reno Videoscope |
| Astellas Pharma US INC | $598.74 | 2019-2023 | Myrbetriq, Xtandi |
| Endo Pharmaceuticals INC. | $431.80 | 2019-2024 | Xiaflex, Aveed, Edex |
| Urogen Pharma, INC. | $349.63 | 2022-2025 | Jelmyto |
| Myriad Genetic Laboratories, INC. | $275.21 | 2021-2023 | Prolaris |
| Coloplast Corp | $262.92 | 2019-2025 | Speedicath |
| Pfizer INC. | $255.03 | 2019-2025 | |
| Urovant Sciences INC | $231.47 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $220.88 | 2022-2025 | |
| Laborie Medical Technologies Corp. | $219.86 | 2022-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Endo USA, INC. | $213.02 | 2024-2025 | Aveed, Xiaflex, Edex |
| Antares Pharma, INC. | $194.66 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Biotech, INC. | $186.91 | 2019-2024 | Erleada, Akeega |
Show all 48 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.